Skip to main content

A feasibility study for SYT-510, a first-in-class drug to treat neuropsychiatric disorders through restoring overall balance in brain chemistry

Project description

Clinical trials planned for game-changing new PTSD drug

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Coordinator

SYNENDOS THERAPEUTICS AG
Address
Swiss Innovation Park, Gewerbestrasse 24
4123 Allschwil
Switzerland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000